Fig. 1From: Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trialStudy flow diagram. All participants in the DObutamine compaREd to MIlrinone study were included in the subgroup analysis. There were 49 (51%) patients on beta-blockers in the milrinone group and 44 (46%) patients on beta-blockers in the dobutamine group for a total of 93 (48%) patients on beta-blockersBack to article page